Tracon Terminates its P-III TAPPAS Trial of TRC105 (carotuximab) + Votrient (pazopanib) for Advanced or Metastatic Angiosarcoma
Shots:
- The termination is based on the recommendation of the Independent Data Monitoring Committee (IDMC) following its review of P-III TAPPAS trials assessing TRC105 (carotuximab) + Votrient (pazopanib) vs Votrient in 340 patients with advanced or metastatic angiosarcoma
- The P-III TAPPAS trial showed disappointing results and demonstrated no efficacy in patients with advanced or metastatic angiosarcoma
- TRC105 (carotuximab) is an antibody to endoglin- currently being evaluated in P-II AVANTE trial in patients with wet AMD and has received ODD in the US & EU. Tracon also develop DE-122 & TRC253 in partnership with Santen & Janssen respectively
Ref: Tracon | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com